IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients

Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab

(2016) A. Martens et al.   CLINICAL CANCER RESEARCH

Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

(2016) Benjamin Weide et al.   CLINICAL CANCER RESEARCH

Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab

(2016) A. Martens et al.   CLINICAL CANCER RESEARCH

Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer

(2015) Kevin C. Conlon et al.   JOURNAL OF CLINICAL ONCOLOGY

Immune Checkpoint Blockade in Cancer Therapy

(2015) Michael A. Postow et al.   JOURNAL OF CLINICAL ONCOLOGY

Investigation of serum proteome alterations in human endometriosis

(2015) Mainak Dutta et al.   Journal of Proteomics

Anchorage independency promoted tumor malignancy of melanoma cells under reattachment through elevated interleukin-8 and CXC chemokine receptor 1 expression

(2015) Wu-Ching Uen et al.   MELANOMA RESEARCH

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

(2015) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients

(2015) Emanuela Romano et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

(2015) M. Vetizou et al.   SCIENCE

Immunologic Correlates in the Course of Treatment With Immunomodulating Antibodies

(2015) Benjamin Weide et al.   SEMINARS IN ONCOLOGY

Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma

(2014) Ester Simeone et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Natural Killer Cells Are Essential for the Ability of BRAF Inhibitors to Control BRAFV600E-Mutant Metastatic Melanoma

(2014) L. Ferrari de Andrade et al.   CANCER RESEARCH

Interleukin-15 in the treatment of cancer

(2014) Thomas A Waldmann   Expert Review of Clinical Immunology

Increased serum levels of interleukin-15 correlate with negative prognostic factors in extranodal NK/T cell lymphoma

(2014) Hua Wang et al.   MEDICAL ONCOLOGY

Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response

(2014) P. Kvistborg et al.   Science Translational Medicine

Enrichment of CD56dimKIR+CD57+ highly cytotoxic NK cells in tumour-infiltrated lymph nodes of melanoma patients

(2014) Talib Hassan Ali et al.   Nature Communications

Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade

(2014) I. P. da Silva et al.   Cancer Immunology Research

Reversal of natural killer cell exhaustion by TIM-3 blockade

(2014) Anne Gallois et al.   OncoImmunology

Biomarkers for Immunostimulatory Monoclonal Antibodies in Combination Strategies for Melanoma and Other Tumor Types

(2013) P. A. Ascierto et al.   CLINICAL CANCER RESEARCH

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma

(2013) Tyler R. Simpson et al.   JOURNAL OF EXPERIMENTAL MEDICINE

The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production

(2013) Stefania Laurent et al.   Journal of Translational Medicine

Therapeutic applications: natural killer cells in the clinic

(2013) J. S. Miller   Hematology-American Society of Hematology Education Program

Enhancement of Tumor-Reactive Cytotoxic CD4+ T-cell Responses after Ipilimumab Treatment in Four Advanced Melanoma Patients

(2013) S. Kitano et al.   Cancer Immunology Research

Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity

(2012) L. C. Ndhlovu et al.   BLOOD

Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9

(2012) M. K. Gleason et al.   BLOOD

Biomarkers on melanoma patient T Cells associated with ipilimumab treatment

(2012) Wenshi Wang et al.   Journal of Translational Medicine

Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity

(2011) Emilie Mamessier et al.   JOURNAL OF CLINICAL INVESTIGATION

Ipilimumab Increases Activated T Cells and Enhances Humoral Immunity in Patients With Advanced Melanoma

(2011) Jeffrey S. Weber et al.   JOURNAL OF IMMUNOTHERAPY

Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors

(2011) Nicolas F Delahaye et al.   NATURE MEDICINE

Synergistic effects of CTLA-4 blockade with tremelimumab and elimination of regulatory T lymphocytes in vitro and in vivo

(2010) Natalia Suarez et al.   INTERNATIONAL JOURNAL OF CANCER

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mature natural killer cells with phenotypic and functional alterations accumulate upon sustained stimulation with IL-15/IL-15R  complexes

(2010) K. G. Elpek et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo

(2009) Tadepally Lakshmikanth et al.   JOURNAL OF CLINICAL INVESTIGATION

CTLA-4 Control over Foxp3+ Regulatory T Cell Function

(2008) K. Wing et al.   SCIENCE